Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effe ...

We are confident that our heritage, success in the last six years, and the talent of our people will help to further establish Daiichi Sankyo as a trusted partner in UK oncology. About the ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking ... reaching billions of people worldwide every day. Reuters provides business ...

With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and ...

This is Okuzawa and starting from April, I'll be taking this heavy responsibility of CEO of Daiichi Sankyo. The purpose is to make a contribution to the rich and healthy life for the people in the ...

Narrow-moat Daiichi Sankyo’s third-quarter earnings were ... opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK ... We are proud to bring Datroway to people living with metastatic HR-positive, HER2-negative breast ...

Daiichi Sankyo has made a little bit of pharma industry ... an aggressive form of brain cancer that affects around 2,500 people in Japan. It's not the first therapy in the oncolytic virus class ...

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan or Dato ... We are proud to bring Datroway to people living with metastatic HR-positive, HER2-negative breast ...

Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's ... reaching billions of people worldwide every day.